Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.35 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 3/20 | 0.33 |
| ▸ | CMA1 | P23946 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603498 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11CYP4Z1GAAALOX5 | |
| SCHEMBL2293437 | 1.00 | CYP4F2 (0.39) | CYP4F2CYP4A11CYP4Z1GAAALOX5 | |
| SCHEMBL2291750 | 0.92 | GAA (0.37) | CYP4F2CYP4A11CYP4Z1GAALTA4H | |
| SCHEMBL4602072 | 0.92 | GAA (0.37) | CYP4F2CYP4A11CYP4Z1GAALTA4H | |
| SCHEMBL2291756 | 0.92 | GAA (0.37) | CYP4F2CYP4A11CYP4Z1GAALTA4H | |
| SCHEMBL15492204 | 0.89 | GAA (0.33) | GAA | |
| SCHEMBL4508822 | 0.86 | MMP12 (0.41) | SMN1; SMN2CTSGCMA1PRSS1CTRB1 | |
| SCHEMBL4508829 | 0.86 | MMP12 (0.41) | SMN1; SMN2CTSGCMA1PRSS1CTRB1 | |
| SCHEMBL7006251 | 0.85 | LTA4H (0.39) | CYP4F2CYP4A11CYP4Z1ALOX5LTA4H | |
| SCHEMBL2292871 | 0.84 | CYP4Z1 (0.43) | CYP4F2CYP4A11CYP4Z1GAAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | CYP4F2 356/4885CYP4A11 54/4885CYP4Z1 1244/4885 |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | TNNI3, TNNT2, FABP3 | CYP4F2 183/4885CYP4A11 831/4885CYP4Z1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.